Important Update to Visitor Policy. Please read important information about COVID-19 vaccination requirements or testing for some visitors. Read our visitor policy.

Emily H. Cheng: Publications

Share

Print

Share

Print

Cheng E.H.-Y., Levine B., Boise L.H., Thompson C.B. and Hardwick J.M. Bax-independent inhibition of apoptosis by Bcl-xL. Nature 1995; 379:554-556.

Cheng E.H.-Y., Nicholas J., Bellows D.S., Hayward G.S., Guo H., Reitz M.S. and Hardwick J.M. A Bcl-2 homolog encoded by Kaposi sarcoma-associated virus, human herpes virus 8, inhibits apoptosis but does not heterodimerize with BAX or BAK inhibits apoptosis. Proc Natl Acad Sci USA 1996; 94:690-694.

Cheng E.H.-Y., Kirsch D.G., Clem R.J., Ravi R., Kastan K.B., Bedi A., Ueno K. and Hardwick J. M. Conversion of Bcl-2 to a Bax-like death effector by caspases. Science 1997; 278:1966-1968.

Clem R.J., Cheng E.H.-Y., Karp C.L., Kirsch D. G., Ueno K., Takahashi A., Kastan M.B., Griffin D.E., Earnshaw W.C., Veliuna M.A. and Hardwick J.M. Modulation of cell death by Bcl-xL through caspase interaction. Proc Natl Acad Sci USA 1998; 95:554-559.

Chau B.N., Cheng E.H.-Y., Kerr D.A. and Hardwick J.M. Aven, a novel inhibitor of caspase activation binds Bcl-xL and Apaf-1. Molecular Cell 2000; 6:31-40.

Wei M.C., Zong W.-X., Cheng E.H.-Y., Lindsten T., Panoutsakopoulou V., Ross A.J., Roth K.A., MacGregor G.R., Thompson C.B. and Korsmeyer S.J. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 2001; 292:727-730.

Cheng E.H.-Y., Wei M.C., Weiler S., Flavell R.A., Mak T.W., Lindsten T. and Korsmeyer S.J. BCL-2, Bcl-xL sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Molecular Cell 2001; 8:705-711.

Scorrano L., Oakes S.A., Opferman J.T., Cheng E.H.-Y., Sorcinelli M.D., Pozzan T. and Korsmeyer S.J. BAX and BAK regulation of endoplasmic reticulum Ca2+: a control point for apoptosis. Science 2003; 300:135-139.

Cheng E.H.-Y., Sheiko T.V., Fisher J.K., Craigen W.J. and Korsmeyer S.J. VDAC2 Inhibits BAK Activation and Mitochondrial Apoptosis. Science 2003; 301:513-517.

Hsieh J. J.-D., Cheng E. H.-Y., Korsmeyer S. J. Taspase1: a threonine aspartase required for cleavage of MLL and proper HOX gene expression. Cell 2003; 115:293-303.

Kim H., Rafiuddin-Shah M., Tu H.-C, Jeffers J., Zambetti G.P., Hsieh J. J.-D., Cheng E.H.-Y. Hierarchical Regulation of Mitochondrion-Dependent Apoptosis by BCL-2 subfamilies. Nature Cell Biology, 2006; 8:1348-1358.

Gavathiotis E., Suzuki M., Davis M.L., Pitter K., Bird G.H., Katz S.G., Tu H.C., Kim H., Cheng E.H.-Y., Tjandra N., Walensky L.D. BAX activation is initiated at a novel interaction site. Nature 2008; 455:1076-1081.

Tu H.-C., Ren D., Wang G., Chen D.Y., Westergard T.D., Kim H., Sasagawa S., Hsieh, J.J-D., Cheng E.H.-Y., The p53-cathepsin axis cooperates with ROS to activate programmed necrotic death upon DNA damage. Proc Natl Acad Sci USA 2009; 106:1093-1098.

Ren D., Kim H., Tu H., Westergard T.D., Fisher J.K., Rubens J.A., Korsmeyer S.J., Hsieh J.J.-D., Cheng E.H.-Y. The VDAC2-BAK Rheostat Controls Thymocyte Survival. Science Signaling 2009; 2: ra48.

Kim H., Tu H., Ren D., Takeuchi O., Jeffers J.R., Zambetti G.P., Hsieh J.J.-D., Cheng E.H.-Y. Stepwise Activation of BAX and BAK by tBID, BIM, and PUMA Initiates Mitochondrial Apoptosis. Molecular Cell 2009; 36:487-499.

Liu H., Takeda S., Kumar R., Westergard T.D., Brown E.J., Pandita T.K., Cheng E.H.-Y., Hsieh J.J.-D. Phosphorylation of MLL by ATR is required for execution of mammalian S-phase checkpoint. Nature 2010; 467:343-346.

Ren D., Tu H., Kim H., Wang G.X., Bean G.R., Takeuchi O., Jeffers J.R., Zambetti G.P., Hsieh J.J.-D., Cheng, E.H.-Y. BID, BIM, and PUMA Are Essential for Activation of the BAX- and BAK-Dependent Cell Death Program. Science 2010; 330:1390-3.

Bean G.R., Ganesan Y.T., Dong Y., Takeda S., Liu H., Chan P.M., Huang Y., Chodosh L.A., Zambetti G.P., Hsieh J.J.-D., Cheng E.H. PUMA and BIM Are Required for Oncogene Inactivation-Induced Apoptosis. Science Signaling 2013; 6:ra20.

Liu H., Westergard T.D., Cashen A., Piwnica-Worms D.R., Kunkle L., Vij R., Pham C.G., DiPersio J., Cheng E.H., Hsieh J.J. Proteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4. Cancer Cell 2014; 25: 530-42.

Chen H.C., Kanai M., Inoue-Yamauchi A., Tu H.C., Huang Y., Ren D., Kim H., Takeda S., Reyna, D.E., Chan, P.M., Tengarai Ganesan Y., Liao C.P., Gavathiotis E., Hsieh J.J., Cheng E.H. An interconnected hierarchical model of cell death regulation by the BCL-2 family. Nature Cell Biology 2015; 17: 1270-1281.

Hakimi A.A., Reznik E., Lee C.H., Creighton C.J., Brannon A.R., Luna A., Aksoy B.A., Liu E.M., Shen R., Lee W., Chen Y., Stirdivant S.M., Russo P., Chen Y.B., Tickoo S.K., Reuter V.E., Cheng E.H., Sander C., Hsieh J.J. An integrated metabolic atlas of clear cell renal cell carcinoma. Cancer Cell 2016; 29: 104-16.

GarnerT.P., ReynaD.E., PriyadarshiA., ChenH.C., LiS., Wu Y., MalashkevichV.N., AlmoS.S., ChengE.H., Gavathiotis E. An autoinhibited dimeric form of BAX regulates the BAX activation pathway. Molecular Cell 2016; 63: 485-97.

Xu J., Pham C., Oyama T., Lee C.H., Rodrik-Outmezguine V., Yao Z., Han S., Chen D., Rosen N., Cheng E.H., Hsieh J.J. Functional convergence and cooperation of mechanistically distinct cancer-associated mTOR activating mutation clusters. J Clin Invest. 2016; 126: 3526-40.

Hosoi K.I., Miyata N., Mukai S., Furuki S., Okumoto K., Cheng E.H., Fujiki Y. The VDAC2-BAK axis regulates peroxisomal membrane permeability. J Cell Biol. 2017; 216: 709-722.

Nargund A.M., Pham C.G., Dong Y., Wang P.I., Osmangeyoglu H.U., Aras O., Xie Y., Oyama T., Takeda S., Ray C. E., Dong Z., Berge M., Hakimi A.A., Monette S., Lekaye C.L., Kourtcher J.A., Tickoo S.K., Leslie C.S., Weinhold N., Lee W., Cheng E.H., and Hsieh J.J. The SWI/SNF protein PBRM1 restrains VHL loss-driven clear cell kidney cancer. Cell Reports 2017; 18: 2893-2906.

Inoue-Yamauchi A., Jeng P.S., Kim K., Chen H.C., Han S., Ganesan Y.T., Ishizawa K., Jebiwott S., Dong Y., Pietanza M.C., Hellmann M.D., Kris M.G., Hsieh J.J., and Cheng E.H. Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy. Nature Communications 2017; 8: 16078.

Wang G., Tu H.C., Dong Y., Skanderup A.J., Wang Y., Takeda S., Ganesan Y.T., Han S., Liu H., Hsieh J.J., Cheng E.H. ΔNp63 inhibits oxidative stress-induced cell death including ferroptosis and cooperates with the BCL-2 family to promote clonogenic survival. Cell Reports 2017; 21: 2926–2939.

Tanaka K, Yu HA, Yang S, Han S, Selcuklu SD, Kim K, Ramani S, Ganesan YT, Moyer A, Sinha S, Xie Y, Ishizawa K, Osmanbeyoglu HU, Lyu Y, Roper N, Guha U, Rudin CM, Kris MG, Hsieh JJ, Cheng EH. Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis. Cancer Cell. 2021 Sep 13;39(9):1245-1261.e6. doi: 10.1016/j.ccell.2021.07.006. Epub 2021 Aug 12. PMCID: PMC8440494.

Xie Y, Sahin M, Sinha S, Wang Y, Nargund AM, Lyu Y, Han S, Dong Y, Hsieh JJ, Leslie CS, Cheng EH. SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes. Nat Cancer. 2022 Feb 3. doi: 10.1038/s43018-021-00316-3. Epub ahead of print.